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Abstract
Background: GHB (gamma-hydroxybutyrate) and its pro-drugs GBL (gamma-butyrolactone) and 1,4-butanediol
(1,4-BD) are central nervous system depressants whose street names include ‘G’ and ‘liquid ecstasy’. They are used
recreationally predominately for their stimulant and pro-sexual effects or for sedation to help with sleep and/or to ‘come
down’ after using stimulant recreational drugs. Although overall population prevalence is low (0.1 %), in some groups
such as men who have sex with men, GHB/GBL use may reach 20 %. GHB/GBL dependence may be associated with
severe withdrawal with individuals presenting either acutely to emergency departments or to addiction services for
support. Benzodiazepines are currently prescribed for GHB/GBL detoxification but do not prevent all complications, such
as behavioural disinhibition, that may require hospitalisation or admission to a high dependency/intensive care unit. The
GABAB receptor mediates most effects of GHB/GBL and the GABAB agonist, baclofen, has shown promise as an adjunct
to benzodiazepines in reducing withdrawal severity when prescribed both during withdrawal and as a 2-day ‘preload’
prior to detoxification. The key aim of this feasibility study is provide information about recruitment and characteristics of
the proposed outcome measure (symptom severity, complications including delirium and treatment escalation) to
inform an application for a definitive randomised placebo controlled trial to determine the role of baclofen in the
management of GHB/GBL withdrawal and whether starting baclofen 2 days earlier improves outcomes further.
Methods/design: This is a prospective, randomised, double-blind, placebo-controlled feasibility study that will recruit
participants (aged over 18 years) who are GHB/GBL-dependent and wish to undergo planned GHB/GBL detoxification or
are at risk of acute withdrawal and are inpatients requiring unplanned withdrawal. We aim to recruit 88 participants: 28
unplanned inpatients and 60 planned outpatients.
During detoxification we will compare baclofen 10 mg three times a day with placebo as an adjunct to the usual
benzodiazepine regimen. In the planned outpatient arm, we will also compare a 2-day preload of baclofen 10 mg three
times a day with placebo. Ratings of GHB/GBL withdrawal, sleep, depression, anxiety as well as GHB/GBL use will be
collected. The main data analyses will be descriptive about recruitment and characterising the impact of adding
baclofen to the usual benzodiazepine regimen on measures and outcomes of GHB/GBL withdrawal to provide estimates
of variability and effect size. A qualitative approach will evaluate research participant and clinician acceptability and data
collected to inform cost-effectiveness.
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Discussion: This feasibility study will inform a randomised controlled trial to establish whether adding baclofen to a
benzodiazepine regimen reduces the severity and complications of GHB/GBL withdrawal.
Trial registration: ISRCTN59911189. Registered 14 October 2015. Protocol: v3.1, 1 February 2016
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Background
GHB/GBL use and dependence
GHB (gamma-hydroxybutyrate) and its related analogues
GBL (gamma-butyrolactone) and 1,4-butanediol (1,4-BD)
are central nervous system depressants and their street
names include ‘G’ and ‘liquid ecstasy’ [1, 2]. GBL and 1,4-
BD are converted to GHB after ingestion and, therefore,
all three drugs have similar pharmacological actions and
profiles [1, 2]. There is limited use of 1,4-BD in the UK
and, therefore, hereafter we will use the term GHB/GBL
to refer to these compounds. They are used recreationally
predominately for their stimulant and pro-sexual effects,
although some individuals use them for their sedative
effects and/or to help ‘come down’ after using stimulant
recreational drugs [3–5]. Although overall population
prevalence of use is low, the Crime Survey for England
and Wales reported that use significantly rose from 0.0 %
in 2010/11 to 0.1 % in 2011/12; subsequent surveys did
not collect GHB/GBL data [6]. However, the use of these
drugs is more common in a number of subpopulation
groups. In particular, in populations such as clubbers and
men who have sex with men (MSM), lifetime prevalence
of GHB/GBL use ranges from 3.9 to 14.3 %, with last-
month prevalence of use of up to 4.6 % [7]. Almost a
quarter of those surveyed in ‘gay-friendly’ South London
dance clubs in July 2011 reported GHB/GBL use that
night, second to mephedrone at 41 % [8]. Similarly,
attendees at two London sexual health clinics (December
2013 to March 2104) reported lifetime prevalence of use
of GHB at 19 % and GBL at 13 % [9].
Reports from the UK’s Advisory Council on Misuse of
Drugs [10] and European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA) [7] have highlighted
the potential for both significant acute toxicity and also
dependence associated with GHB/GBL. The latest data
from Public Health England reports that the numbers of
people presenting to treatment services with problems
with GHB/GBL continue to rise from 18 (2 % of new
presentations involving ‘club drugs’ (methamphetamine,
mephedrone, ketamine, ecstasy, and GHB/GBL)) of
those seeking treatment in 2005–2006 to 249 (5 %) in
2013–2014 [11] and the number of deaths implicating
GHB are also rising from none in 1993 to 12–20/year in
2008–2012 [12]. Our clinical experience is consistent
with this. Presentations with acute GHB/GBL toxicity to
the emergency department (ED) and Clinical Toxicology
Service (one of the sites in this study) at Guy’s and St.
Thomas’s Hospital Foundation Trust (GSTT) increased
from 158 in 2006 to 270 in 2010 [13]; and there has
been an increase in the numbers of individuals seeking
help from services such as Antidote (supporting the les-
bian, gay, bisexual and transgender (LGBT) community)
and the Club Drug Clinic, Central North West London
NHS Foundation Trust (CNWL) for GHB-related prob-
lems. Antidote has seen an increase in GHB-related
problems from 1.7 % (n = 3) of total referrals in 2005 to
57 % (n = 317) in 2010 and 44 % (n = 334) in 2013–2014.
GHB/GBL use is associated with a risk of physical de-
pendence and a potentially life-threatening withdrawal
syndrome, unlike other club drugs such as stimulants
which do not have a pronounced withdrawal syndrome
[14]. Therefore, a disproportionate number of GHB/GBL-
dependent users compared with other club drug users
require help for a potentially life-threatening withdrawal
syndrome. Management of GHB/GBL withdrawal or
detoxification can present challenges to clinicians and
dependent users due to the rapidity of onset of the with-
drawal and the severe clinical features that can occur.
Regular use of GHB/GBL (typically multiple times per day
every day over a period of at least a few months) can lead
to dependence with dependent users typically using the
drug every 1–4 h to prevent the onset of withdrawal
[15–18]. Withdrawal symptoms occur typically within
hours following last use due to GHB/GBL’s rapid
elimination (T1/2 is approximately 27 min) and may
also occur during recovery from acute intoxication
(overdose) [2, 11, 18, 19]. A proportion of the pa-
tients with GHB dependence may, therefore, use alco-
hol or other drugs such as benzodiazepines, ‘Z drugs’
(e.g. zopiclone) and/or baclofen to self-manage with-
drawal symptoms, insomnia and cravings. Typically
these are used to help increase the time between dos-
ing overnight to enable them to sleep. The clinical
features of GHB withdrawal are similar to alcohol
withdrawal but often with more rapid onset. GHB
withdrawal can also resemble acute stimulant toxicity
and coingestion of other drugs. Identification of GHB
dependence and withdrawal can be complicated by a
lack of awareness by nonspecialist centres, particularly
in emergency cases [20].
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GHB/GBL withdrawal and its treatment
GHB/GBL withdrawal has many similar features to
alcohol withdrawal, including tremor, sweating, anxiety,
agitation and confusion; however, it is generally more
severe, has a more rapid onset and more prominent
neuropsychiatric features such as delirium and psychosis
[2, 15, 18]. In common with alcohol withdrawal, benzo-
diazepines have been the pharmacotherapeutic mainstay
for GHB/GBL withdrawal [18]. However, our clinical
experience suggests that using benzodiazepines alone
may be insufficient, with up to 50 % of individuals
presenting to our ED and initially 4 % of those in our
outpatient clinic requiring acute medical care [21, 22].
This latter group had either developed significant
delirium and/or worsening of their initial acute delirium
on presentation that required escalation of treatment, in-
cluding admission to intensive care and use of additional
sedatives (e.g. barbiturates or propofol) with the associ-
ated intubation and mechanical ventilation for airway
support as described [15]. Acute delirium, agitation and/
or psychosis results in further risks to the individual, as
well as to the staff treating them due to the severity of
their agitation and violent behaviour. There has been
one death reported as a ‘complication of GHB/GBL
withdrawal’. The individual in this case was treated with
benzodiazepines for 12 days, developed pneumonia and
suffered a cardiac arrest and we feel that the significance
of the GHB dependency/withdrawal in the death is un-
clear and it is likely that the death is not directly related
to dependence/withdrawal [23]. Despite the severity of
GHB/GBL withdrawal and concerns about how to best
manage unplanned and planned detoxification, at this
time there is no systematic evidence base on which to
base a nationally or internationally agreed treatment
protocol. One review produced an algorithm based on
the amount of use and the presence of delirium [24]. For
those with severe dependence (more than three doses of
GHB/GBL per 24 h or over 30 g GHB or/over
15 g GBL) and ‘medical complications’, admission for de-
toxification and supportive medical care with high-dose
diazepam (150–200 mg/24 h) was suggested. Pentobar-
bital (barbiturate) in the intensive care unit (ICU) was
suggested for treating those presenting with delirium.
However, it was not clear how long to use pentobarbital
for or what to do in those who do not respond to this
treatment escalation. For those without delirium, diaze-
pam reducing from 80 to 150 mg per day over 7 days
whilst an inpatient was proposed. For those using less
GHB/GBL, outpatient management with diazepam redu-
cing from 20 to 40 mg per day over 7 days was sug-
gested. Given the complexity, rapidity of onset of
symptoms and complications of withdrawal, such as
acute severe delirium, it is important that daily out-
patient supervision of GHB/GBL withdrawal occurs in a
setting in which admission to an acute hospital is pos-
sible should complications arise [25].
Various other pharmacological approaches have been
investigated. One trial compared lorazepam and pen-
tobarbital in inpatients for GHB/GBL withdrawal;
however, this was not completed due to the inability
to recruit sufficient GHB-dependent individuals [26].
Whilst pentobarbital is safe to use in hospital, due to
the potential risk of coma and lethal toxicity it is not
appropriate for use in community/outpatient detoxifi-
cation. A Dutch pilot uncontrolled study reported that
a reducing regimen of GHB/GBL successfully treated
withdrawal and prevented complications, such as
delirium, in 23 GHB/GBL-dependent inpatients [27].
GHB in the pharmaceutical preparation sodium oxy-
bate is licensed in the UK for the treatment of nar-
colepsy associated with cataplexy in specialist sleep
services. Current UK prescribing, storage and adminis-
tration controls (due to the legal status of GHB under
the UK Misuse of Drugs Act, 1971) are likely to be
practical considerations that limit its usefulness in
managing GHB/GBL withdrawal (due to delays in
treatment administration). Antipsychotic agents may
lower the seizure threshold increasing the risk of GHB
withdrawal-related seizures. However, they may also
interact with GHB’s effects on the dopaminergic system
increasing the risk of neuroleptic malignant syndrome
[17, 28].
In summary, a reducing regimen of benzodiazepines
alone for GHB/GBL withdrawal is currently considered
‘standard’ treatment and as such is the current ‘best
practice’; although in a significant proportion of indi-
viduals benzodiazepines alone may be insufficient.
The limited research almost always suggests benzodi-
azepines as the core treatment, with a range of other
options having been suggested as helpful of which
baclofen has strong pharmacological validity (see next
section).
GHB/GBL withdrawal and the GABAB system
In addition to its activity at endogenous GHB receptors
GHB acts at GABAB receptors, which play a key role in
withdrawal since GABAB antagonists precipitate with-
drawal in GHB-dependent nonhuman primates [1, 29]
and can block GHB-induced respiratory depression [30].
Benzodiazepines work through GABAA receptors; how-
ever, GHB has limited activity at these receptors, likely
explaining their apparently incomplete clinical effective-
ness in acute GHB withdrawal. The GABAB agonist
baclofen has, therefore, been used on an unlicensed
named-patient basis as an adjunct to benzodiazepines to
manage GHB/GBL withdrawal by the authors and others
[18, 31]. Baclofen is currently only licensed in the UK
Lingford-Hughes et al. Trials  (2016) 17:472 Page 3 of 11
for the management of muscle spasticity in multiple
sclerosis and other conditions.
An uncontrolled case series in 19 GHB/GBL-
dependent patients, all of whom except for 2 underwent
outpatient treatment, reported that baclofen (10 mg
three times a day) in addition to high-dose diazepam
during the initial 4–5 days of GHB/GBL detoxification,
resulted in no transfers to ICU and several patients
commented that baclofen was helpful [18]. Furthermore,
the experience of clinical toxicologists and addiction
specialists in the UK, including those involved in this
study, has been that baclofen is helpful in reducing the
complications from GHB/GBL withdrawal. Consequently,
the recent update of the British Association for Psycho-
pharmacology’s addiction guidelines [25] suggested using
baclofen (10 mg three times a day) as an adjunct to benzo-
diazepines for GHB/GBL withdrawal.
Furthermore, our clinical experience of GHB/GBL
withdrawal in outpatient settings has been that patients
who slowly reduce their GHB/GBL use describe signifi-
cant anxiety and cravings during the few days before
commencing medically assisted detoxification. For some,
this acted as a deterrent to attending for treatment and
a trigger for using higher doses of GHB/GBL. Conse-
quently, we have initially used baclofen 2 days prior to
stopping GHB/GBL in a small number of patients. There
was very positive feedback from patients regarding the
benefit, particularly in terms of reduced cravings and
helping to stabilise pre-detoxification GHB use. The use
of baclofen in our outpatient clinical service prior to ini-
tiating medically assisted detoxification has now become
more widespread. The 2 days of pre-detoxification
‘preloading’ of baclofen at a standard dose of 10 mg
three times a day has not resulted in any clinical
incidents in relation to baclofen. This preloading with
baclofen has previously not been formally studied to
determine the usefulness of baclofen itself, neither has
whether some of the reported benefits relate more to
engagement with drug treatment services pre-
detoxification than to baclofen itself.
Baclofen has been licensed in the UK for many years
for the treatment of spasticity (maximum, 100 mg per
day) and can be safely prescribed to a wide range of pa-
tients (see Summary of Product Characteristics (SPC),
https://www.medicines.org.uk/emc/medicine/23850).
Our clinical experience is that it is associated with few
side effects. Whilst a withdrawal state is recognised for
baclofen, this is unlikely to occur with its use in acute
GHB withdrawal due to the short duration (7 to 10 days)
of baclofen use in this indication. We suggest that the
risk of complications from baclofen withdrawal is con-
siderably less than that of inadequately managed GHB/
GBL withdrawal [15, 18]. Nevertheless, whilst the use of
baclofen holds promise, there are potential adverse
effects on cardiovascular, neurological and respiratory
systems so controlled data is urgently required to deter-
mine its efficacy and safety in GHB/GBL withdrawal.
Optimising outpatient treatment to reduce the risk of
complications and hospital admission is important since
many individuals decline admission [17, 25]. Despite this
complexity and its impact on, and cost to, the individual
and the NHS, there is limited knowledge about how to
best treat people in planned or unplanned GHB/GBL
withdrawal.
Primary and secondary objectives
The primary objective of this study is to investigate the
feasibility of recruiting GHB/GBL-dependent patients
and to characterise the impact of adding baclofen to a
standard benzodiazepine regimen for the management of
GHB/GBL withdrawal in both outpatient (community)
and inpatient general hospital settings.
There are several other secondary objectives. These
are to examine:
 Withdrawal symptoms and complications, such as
delirium and the requirement for treatment
escalation, during detoxification in two populations:
those presenting to an ED requiring immediate
acute withdrawal management (unplanned) and
those presenting to a specialist outpatient Club Drug
Clinic requiring GHB/GBL detoxification (planned)
 Whether, as part of a planned detoxification, starting
baclofen 2 days prior to stopping GHB/GBL confers
additional benefits in our proposed primary outcome
measures (symptom severity, complications such as
delirium and requirement for treatment escalation)
 Recruitment rate monitoring and manage any
difficulties
 The impact of GHB/GBL withdrawal on secondary
outcome measures (anxiety, depression, sleep,
quality of life)
 The impact of study participation on GHB/GBL use
up to 1 month post randomisation and other
alcohol/drug use
 The views of the research participants and staff
about the acceptability of the study design
 Preliminary information gathered regarding costs of
GHB/GBL withdrawal and its management to
develop a full economic analysis in a definitive trial
Methods/design
This is a prospective, randomised, double-blind, placebo-
controlled trial to assess the feasibility of undertaking
a definitive trial investigating the efficacy of baclofen
in treating GHB/GBL withdrawal, both in planned and
unplanned withdrawal using both quantitative and quali-
tative approaches. The optimal recruitment rate and
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strategies and characteristics of the proposed primary
outcome measures (symptom severity, complications, and
requirement for treatment escalation) will be assessed.
Ethical approval has been obtained from National
Research Ethics Service Committee London – Dulwich
and the EUDRACT number is 2013-005319-28.
Research settings
The study will recruit from two services where individuals
present for treatment of GHB/GBL withdrawal. The
CNWL Club Drug Clinic, based in Central London, UK is
an outpatient clinic where individuals are referred or self-
present for treatment for GHB/GBL dependence and may
undergo planned detoxification as part of their treatment
package, and secondly, to a specialist Clinical Toxicology
Service at Guy’s and St. Thomas’ NHS Foundation Trust,
London, UK for those who present with unplanned with-
drawal requiring immediate management. For planned
detoxification group recruitment, we have produced a trial
poster and short information sheet for use at our linked
clinical services to ensure an adequate appropriate recruit-
ment rate. We will display this poster at such clinical
services and staff will be encouraged to provide a copy of
the short information sheet for planned withdrawal.
Participants
Inclusion criteria
Any individual who is over 18 years old, is either in ac-
tive GHB/GBL withdrawal or has underlying GHB/GBL
dependence and wishes to undergo GHB/GBL detoxifi-
cation or is thought to have underlying GHB/GBL
dependence and is at risk of acute withdrawal and, for
the outpatient arm only, who is registered with a drug
treatment service, will be eligible for the study.
Exclusion criteria
An individual will not be eligible for inclusion in this
study if they are unable to provide written informed
consent and any of the following criteria apply: the
clinician decides that medication is not required for the
management of GHB/GBL withdrawal; if medication is
indicated but the patient lacks capacity to consent, is
unable to take oral medication or is unable to take
baclofen according to SPC due to known hypersensitivity
to baclofen or any of the excipients, hereditary problems
of galactose intolerance, the Lapp lactase deficiency or
glucose-galactose malabsorption, active peptic ulceration
or porphyria. In addition, for those with epilepsy that is
not well-controlled, either with or without medication,
or those with end-stage renal failure (Chronic Kidney
Disease (CKD) stage 5, GFR below 15 mL/min) (which
have special warnings and precautions for use, according
to the SPC) will not be entered since the risk versus
benefit ratio for prescribing is not in favour of
prescribing baclofen. In addition, participants who are
unable to follow the study protocol due to serious
mental health disorder, e.g. enduring psychotic illness or
suicidal intent will not be eligible. Further, any partici-
pant who has taken any investigational drug within
30 days prior to drug administration or any woman
refusing a pregnancy test will not be eligible.
Randomisation
An assessment of eligibility will be made by a phys-
ician following discussion with the potential partici-
pant and review of the accessible medical records.
For some participants wishing to participate in the
study but where there is limited or no access to
medical records, the individual will be included in the
trial unless one or more of the eligibility criteria are
known not to be met. Informed consent will be ob-
tained by a member of the study team.
To be able to respond to the urgent needs of people
who are at high risk of withdrawing from GHB/GBL in a
timely manner, the study medication will be pre-packed
and pre-randomised and stored at both study sites.
Randomisation codes in blocks of 4 (for the planned
withdrawal group) and blocks of 15 (for the unplanned
withdrawal group) will be generated by the trial statisti-
cian. Those eligible for inclusion will be randomised to
baclofen or placebo by taking the next lowest consecu-
tively numbered pack from storage cupboards in the
respective treatment centre.
If eligible, have given informed consent and follow-
ing baseline assessment, the participants are allocated
as follows (see Fig. 1a and b). Those in the planned
arm will receive a preload before their detoxification
proper and will be allocated to one of three groups:
preload of placebo (one tablet three times a day)
followed by the benzodiazepine GHB/GBL detoxifica-
tion regimen with the study medication, baclofen
(10 mg three times a day) or placebo (one tablet
three times a day) for up to 10 days, or preload of
baclofen (10 mg three times a day) followed by the
benzodiazepine GHB/GBL detoxification regimen with
baclofen (10 mg three times a day) for up to 10 days.
Those in the unplanned arm will receive their benzo-
diazepine detoxification regimen for GHB/GBL with-
drawal with the study medication, baclofen (10 mg
three times a day) or placebo (one tablet three times
a day) for up to 10 days. In both unplanned and
planned GHB/GBL withdrawal, clinicians will use the
benzodiazepine and dosing regimen that they consider
appropriate. The study medication will be discontin-
ued at the same time as the benzodiazepine, with the
decision about when both medications are to be
discontinued made by their clinician.
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Assessment and outcome measures
Data will be collected to inform the primary and second-
ary outcome measures in the definitive trial (see Table 1).
The proposed primary outcome measures include symp-
tom severity, complications and requirement for treat-
ment escalation, and the proposed secondary outcomes
include change in anxiety, depression, sleep and quality
of life as well as relapse to GHB/GBL use or change in
other illicit drug or alcohol use 30 days after the start of
detoxification.
On the first day of GHB/GBL detoxification, ratings
will be obtained from each participant of their symp-
toms of GHB/GBL withdrawal using a scale widely
used for alcohol withdrawal – the Clinical Institute
Withdrawal Assessment for Alcohol (CIWA-Ar) which
is currently used clinically by teams to monitor GHB/
GBL withdrawal [32–35]. The CIWA-Ar may not
adequately capture all neuropsychiatric symptoms/
signs [32, 33] and the Sedation Assessment Tool (SAT)
will assess behavioural disturbance [36]. Depressive
(Patient Health Questionnaire-9 (PHQ-9); [37]) and
anxiety (Generalized Anxiety Disorder-7 (GAD-7);
[38]) symptoms will be assessed using scales that
are already in routine clinical use. We will also re-
cord sleep pattern using a questionnaire [39]. Any
medication taken by the time of the ratings will be
recorded. Blood pressure, respiratory rate, oxygen
saturation and pulse will also be recorded when the
CIWA-Ar is completed. Since this is a pragmatic trial,
we aim to minimise any extra tests or investigations
and research participants will receive standard medical
care as usual. If, as part of this standard medical care,
blood and/or urine will be collected for toxicological
screening for recreational drugs/novel psychoactive
substances, the results will be recorded but not sought
solely for the purposes of this study.
During detoxification, daily assessments will record
the withdrawal assessment scale (CIWA-Ar; [29]), be-
havioural disturbance (SAT; [36]), sleep pattern, any
use of other drugs/novel psychoactive substances/
alcohol and nicotine (including substitution), as well
as when they took any medication. On the last day of
taking detoxification medication (or the next working
day for outpatients where this falls on a weekend/
public holiday), withdrawal, depressive and anxiety
symptoms (PHQ-9: [37]; GAD-7: [38]) and sleep
pattern will be recorded for all participants. Research
participant satisfaction will be measured with the
Client Satisfaction Questionnaire-8 (CSQ-8; [40, 41]).
Any information not already obtained or previously
available will also be completed and will include the
following: using a semistructured questionnaire: years
of GHB/GBL use, the amount of GHB/GBL used in
the week prior to detoxification and the amount in a
typical day/week, pattern of use, whether they are self-
reported ‘dependent’ on any of these medication(s)
that have been used to help self-treat or prevent previ-
ous withdrawal. Previous psychiatric and medical his-
tory, other drug or alcohol use including nicotine and
determination of any dependence will be similarly
established as well as using time-life follow-back, the
alcohol screening questionnaire (Alcohol Use Disor-
ders Identification Test (AUDIT); [42]) and appropri-
ate parts of the mandatory Treatment Outcomes
Profile (TOP; [43]) used in substance misuse services
will be completed.
Regarding medication, the total amount of benzodi-
azepine prescribed, its dosing regimen and quantity
taken will be recorded. Use of any other medication
during the detoxification will also be recorded.
Any complications arising during preload or detoxifi-
cation will be recorded. These will be classified as
adverse events if they are not one of the following prede-
termined events which are known to occur in acute
GHB/GBL withdrawal or detoxification: agitation or
aggression, hallucinations (visual, auditory and/or tact-
ile), tachycardia, seizures, ataxia, sedation, tremor and/or
sweating. All adverse events occurring from the time a
participant signs the Consent Form until completion
A
B
Fig. 1 a CNWL Club Drug Clinic – Planned (outpatient) withdrawal,
N = 60 (three groups). b GSTT clinical toxicology service – Unplanned
(inpatient) withdrawal, N = 28 (two groups). CNWL Central North West
London NHS Foundation Trust, GSTT Guy’s and St. Thomas’s NHS
Foundation Trust
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of the last study-related procedure will be recorded in
the Case Report Form. Any serious adverse event
which occurs in a participant will be reported imme-
diately to the chief investigator (CI) and sponsor and,
if stated orally, will be followed by a detailed written
report.
On day 30 after the start of detoxification (benzodi-
azepine detoxification, not preload), the researcher will
contact the research participant to obtain information
about any subsequent use of GHB/GBL, other recre-
ational drugs/novel psychoactive substances/alcohol as
well as any medication (prescribed or otherwise
obtained) taken and psychosocial treatment/support
received for their GHB/GBL dependence. In addition,
any issues or events that could be related to their detoxi-
fication will be recorded.
Patients will be asked to return any remaining study
medication to the clinic so that a pill count can be
performed to assess compliance.
Study medication discontinuation and withdrawal from
the study
In accordance with the current revision of the Declaration
of Helsinki (amended October 2000, with additional foot-
notes added in 2002 and 2004), a participant has the right
to stop trial treatment and to withdraw from the trial at
any time and for any reason, without prejudice to his or
her future medical care by the physician or at the institu-
tion, and is not obliged to give his or her reasons for doing
so. The principal investigator’s clinical judgement will de-
termine whether or not an adverse event is of sufficient
severity to require discontinuation of the study treatment.
A participant who discontinues the study medication be-
fore the end of their detoxification will not be withdrawn
from the study. Provided they have not withdrawn their
consent, they would continue to be followed up to
enable an intention-to-treat analysis. In addition, as this
is a feasibility study, they may be approached for the
qualitative study.
Table 1 Assessment schedule of quantitative measures
Assessment Baseline or as soon as
data can be obtained
Daily during detoxification Last day of
detoxification or
next working day





CIWA-Ar ✓ ✓ ✓ ✓ ✓
Sedation Assessment Tool ✓ ✓ ✓ ✓
Depression (PHQ-9) ✓ ✓
Anxiety (GAD-7) ✓ ✓
Sleep pattern questionnaire ✓ ✓ ✓ ✓ ✓
Vital signs ✓
Psychiatric history ✓
Relevant past medical history ✓
Concomitant prescribed medication ✓ ✓ ✓ ✓ ✓
Lifetime GHB/GBL use questionnaire ✓
Daily drug/alcohol/nicotine use
questionnaire
✓ ✓ ✓ ✓




Treatment Outcome Profile ✓
Client Satisfaction Questionnaire (CSQ-8) ✓
Adverse events ✓ ✓ ✓ ✓




Follow-up GHB/GBL use questionnaire ✓
Follow-up drug/alcohol use questionnaire ✓
Follow-up service use questionnaire ✓
AUDIT Alcohol Use Disorders Identification Test, CIWA-Ar Clinical Institute Withdrawal Assessment for Alcohol, GAD-7 Generalised Anxiety Disorder-7,
GBL gamma-butyrolactone, GHB gamma-hydroxybutyrate, PHQ-9 Patient Health Questionnaire-9
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Study unblinding
Masking of treatment allocation will be maintained dur-
ing an individual’s participation in the trial unless any of
the following occur: a serious adverse event arises that
clinically requires disclosure or another clinical reason
to need to know the allocation such as to start the par-
ticipant on medication which has a risk of interaction.
The 24-h emergency unblinding service will allow a med-
ical request for unblinding in the event of a medical emer-
gency. Procedures will be put in place to verify the
identity of the participant and caller, and the decision on
whether to reveal the study medication allocation will be
based on a set of criteria for judging clinical need. All re-
quests for unblinding will be recorded.
Sample size
The aim is to recruit 88 research participants who are
undergoing GHB/GBL detoxification: 60 planned outpa-
tients and 28 unplanned inpatients.
Qualitative process evaluation: research participant and
clinician acceptability
We will undertake qualitative, semistructured, one-to-one
interviews with 12 research participants, 6 from each site.
Informed consent will be separately sought for this aspect
of the study. Participants will be sampled purposively to
represent key case-mix variables and treatment allocation.
These interviews will investigate (1) participants’ experi-
ence and acceptance of the study procedures (notably
recruitment, randomisation and outcome assessment
procedures) and (2) their treatment experience. The inter-
views will be conducted using a topic guide. This will be
drafted on the basis of the study aims, relevant scientific
literature and clinical experience, but there will be scope
for iterative development of the guide as data collection
and analysis progress. Participants who have undergone a
previous detoxification will be asked to reflect on how the
trial detoxification compared with previous ones.
In addition, two focus groups involving the clinical
teams from each site will also be conducted. These will
explore clinician experience of the trial and the accept-
ability of trial procedures. Key senior members of staff
will also be offered a one-to-one semistructured interview.
All interviews and focus groups will be audio-recorded,
transcribed and analysed using a thematic framework
approach and managed using NVivo (Scolari/Sage) com-
puter software. Initial coding frameworks for both partici-
pant and staff datasets will be based on the study aims of
how feasible and acceptable it is to undertake a definitive
trial, but subthemes will be further developed through
analytic induction and grounded in the data. This will be
revised iteratively as data collection and analysis progress.
Cost-effectiveness
Data will be collected to inform the undertaking of a full
economic evaluation in the definitive randomised con-
trolled trial (RCT) by piloting the data collection
methods that would be used in such a full trial. Piloting
data collection instruments will show the feasibility of
recording service use information from the population
and identify the services and other costs to participants
that would need to be included in a full economic evalu-
ation of a phase III trial.
Safety monitoring plan
An Independent Data Monitoring and Ethics Committee
(IDMEC) will be established to provide overall supervi-
sion of the trial and ensure that it is being conducted in
accordance with the principles of Good Clinical Practice
(GCP) and the relevant regulations. It will report to the
Trial Steering Committee which provides overall super-
vision for the GHB trial on behalf of the trial sponsor
and the trial funder, ensures that the trial is appropri-
ately conducted, and provides advice, through its chair,
to the Trial Management Group.
The end of the trial is defined as completion of follow-
up of, or three attempts to contact, the last participant
randomised to the study medication. The trial may
terminate before all (n = 88) participants have been
recruited if we have obtained sufficient information
about recruitment, engagement and/or evaluation of
outcome measures.
The NHS Indemnity Scheme applies and provides un-
limited cover for NHS staff, medical academic staff with
honorary contracts and those conducting research, for
negligent harm. Non-negligent harm (i.e. harm that has
been caused through no fault of those conducting re-
search) is not covered by this scheme; however, ex gratia
payments may be considered by the trust in limited
circumstances.
Trial monitoring
Each site in the trial will receive two on-site monitor
visits, firstly when five participants have been rando-
mised to the trial and a second site visit 6–9 months
from the time of site activation. Additional monitor
visits will be conducted if required. These will be
conducted by the sponsor, CI and trial manager.
Data
The anonymised data will be stored on a laptop and
backed up on a secure server. The personal datasheet
and code associated with that person will be kept locked
up. All data handling and record keeping will adhere to
the Data Protection Act 1998. Regarding access to
source data, the sponsor and investigators will permit
monitoring, audits, Research Ethics Committee (REC)
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and Medicine and Healthcare products Regulatory
Agency (MHRA) review (as applicable) and provide dir-
ect access to source data and documents as appropriate.
Data analysis
The primary focus of this study is to assess the feasibility
of undertaking a definitive trial. In particular, we will char-
acterise the optimal recruitment rate and strategies and
characteristics of the proposed primary outcome measures
(symptom severity, complications, and requirement for
treatment escalation). The main analyses will be descrip-
tive and provide estimates of variability and effect size
with 95 % confidence intervals. This will include the rate
of recruitment, the proportion of people approached who
consent to randomisation, the proportion who complete
detoxification and the proportion who will complete the
follow-up assessment. We will also describe the distribu-
tion of scores on the primary outcomes and estimate the
variance of the measure in this population. Data for our
proposed secondary outcomes in the definitive trial will
include change in anxiety, depression, sleep and quality of
life as well as relapse to GHB/GBL use or change in other
illicit drug or alcohol use 30 days after the start of detoxifi-
cation. We will also identify appropriate criteria, e.g.
benzodiazepine requirement or withdrawal score for mini-
misation or stratification in the full RCT.
We will use ANCOVA adjusting for patients’ character-
istics and relevant clinical data. Where there is follow-up,
methods applied to longitudinal data will be appropriate
since they are able to detect significant differences
between arms but they can also detect changes of the
outcome measure(s) over time. We will also conduct an
interim analysis to characterise the number of adverse
events in each arm as described above.
An interim analysis to characterise the number of ad-
verse events in each arm will also be conducted. Treat-
ment escalation (i.e. admission to ICU for those
presenting to the ED (unplanned) and admission to the
general hospital for those in the Club Drug Clinic
(planned)) will be closely monitored. From our clinical
experience of complications from GHB/GBL withdrawal,
if five individuals in any one group require treatment
escalation, the sponsor and IDMEC will be immediately
informed and recruitment suspended until there has
been a discussion and consideration of the protocol and
trial continuing. Stopping rules will also be agreed which
specify the point at which interim results will be judged
to be sufficiently conclusive for it to be appropriate for
the IDMEC to recommend that they consider early
termination of the trial.
Trial dissemination
The outcome of the trial will be communicated to the
clinical and academic communities through presentations
at conferences and meetings including those attended by
users, and publications in peer-reviewed journals and
general media if appropriate. These will be completed by
members of the study team. These will be in line with
NIHR publication procedures.
Discussion
Whilst GHB/GBL may not be widely used by the general
population, there is greater use in certain subpopulations
such as gay and bisexual males (GBM). Regular use of
GHB and its related analogues can lead to the development
of physical dependency and an associated withdrawal
syndrome on stopping use [1, 2]. This typically is rapid in
onset after last dose and may mimic other conditions (e.g.
acute stimulant toxicity, acute alcohol withdrawal) making
its diagnosis and management challenging for clinicians
[2, 11, 14]. This is particularly of concern in areas where
GHB and related analogue use is low, so there may be a
lack of awareness of the potential for dependency and
withdrawal. A proportion of individuals with GHB-related
withdrawal may require more intensive sedation and sub-
sequent admission to HDU/ICU to ensure not only their
safety, but also that of the staff caring for them. This
incurs significant costs to the individual through length of
stay and potential for ICU-related complications, as well
as to the NHS and wider society due to the required
resource utilisation.
There is much anecdotal evidence that the current clin-
ical practice of using benzodiazepines alone as initial treat-
ment may be insufficient to adequately manage GHB/GBL
withdrawal and prevent the requirement for treatment es-
calation. Since GHB/GBL acts as a GABAB receptor agon-
ist, using another GABAB agonist, baclofen, to attenuate
withdrawal has pharmacological validity. Our clinical ex-
perience, and that of others, is that the addition of baclo-
fen (10 mg three times a day) to benzodiazepines does
indeed reduce GHB/GBL withdrawal symptoms and its
associated complications [11, 14]. Furthermore, preloading
with baclofen for 2 days prior to detoxification appears to
provide additional benefits. When designing this trial, we
were not aware that this is undertaken routinely outside
our specialist clinic and it is important to understand its
role in improving and managing GHB/GBL withdrawal. A
similar approach may be used by some clinicians for par-
ticular patients to help them to prepare for their alcohol
detoxification by reducing cravings and excessive con-
sumption prior to starting their detoxification proper.
Due to its use in particular communities, specific ad-
diction services have evolved with expertise in managing
GHB/GBL withdrawal. Similarly, presentations to EDs
vary depending on local clubs and nightlife, since
individuals who frequent these tend to also live in the
local area. The two services in this study have such local
communities and have developed their services to meet
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the local needs. They are, therefore, well-placed to con-
duct this study due to their experience and the regular
presentations of those with GHB/GBL withdrawal. There
is local support and much user interest in this study.
In order to determine whether baclofen is a useful
adjunct and to meet thresholds required by national
guidelines, e.g. NICE, a trial is still required; without
such a trial the use of baclofen will remain based on
anecdotal evidence. We are not aware of any other trial
using baclofen in GHB withdrawal nor has any other
pharmacological approach been shown to be robustly
effective or appropriate for community-based detoxifica-
tion. Importantly this trial also seeks to establish whether
the use of baclofen prior to starting detoxification, i.e. a
preload improves symptom control and reduces complica-
tions during GHB detoxification. This is a novel aspect of
the study and addresses a critical question.
Trial status
The study has received favourable opinions from the
MHRA and the REC. The aim is to start recruitment by
Spring 2016.
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